drugset / Trial / NCT02362529

Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder

NCT02362529

Phase 0 Completed 115 enrolled Centre for Addiction and Mental Health
RandomizedSingle-groupQuadruple-blindBasic science

Summary

The purpose of this study is to determine if translocator protein total distribution volume (TSPO VT) is elevated in major depressive disorder that is not responding to medication and if adding minocycline can affect TSPO VT. Many remain treatment resistant with common antidepressant treatments and the investigators think it may be due to poor targeting of brain pathologies.

Timeline

Start
2015-02
Primary completion
2019-04
Completion
2019-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg Oral
Subject Minocycline Small molecule 100 mg Oral